Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Lancet
; 401(10373): 281-293, 2023 01 28.
Article
in En
| MEDLINE
| ID: mdl-36566761
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2023
Document type:
Article
Country of publication:
Reino Unido